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Background: Candidiasis control should include monitoring the epidemiology and resistance to various antifungal 
agents. In this study, the researchers investigated the Candida species recovered from clinical specimens at particular 
geographic areas or hospitals. 
 
Objective: The present study is geared toward the evaluation of antifungal drug usage at Korean hospitals in 2016. 
It is also essential that species distribution and antifungal susceptibilities of Candida isolates should be looked into 
to provide important data that can help devise therapeutic strategies to control the disease. 
 
Methods: Systemic antifungal agent usage over a one-year period was investigated at 10 Korean hospitals. 
Identification and antifungal susceptibility tests were performed on clinical isolates of the Candida species, which 
were collected over a three-month period. 
 
Results: The total antifungal usage in each hospital ranged from 7.7 to 158.9 defined daily doses (DDDs) per 1,000 
patient days. Fluconazole was most commonly used (37.1%), followed by amphotericin B (30.6%), itraconazole 
(9.7%), echinocandins (8.8%), voriconazole (7.5%), and posaconazole (6.3%), respectively. Among 274 Candida 
isolates, C. albicans was the most frequently recovered (51.1%), followed by C. glabrata (15.7%), C. tropicalis 
(15.0%), and C. parapsilosis (13.5%), respectively. Through the application of either species-specific clinical 
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INTRODUCTION 
Candida species are commonly found as normal flora, but 
they can cause a variety of opportunistic infections such as 
oropharyngitis, esophagitis, vulvovaginitis, urinary tract infec- 
tion, meningitis, endophthalmitis, endocarditis, peritonitis, 
osteomyelitis, and candidemia1,2. Candidiasis control should 
include monitoring the Candida species' epidemiology and 
resistance to various antifungal agents1,2. Antifungal usage is 
associated with the distribution and antifungal susceptibility 
of Candida species3-5. According to previous multicenter studies 
conducted in South Korea since 20043,5,6, the pattern of anti- 
fungal drug usage, the rank order of occurrence, and anti- 
fungal susceptibilities of disease-causing Candida species varied 
across hospitals and different time periods. This multicenter 
study was performed in order to investigate the antifungal drug 
usage in Korean hospitals and the antifungal susceptibility of 
Candida species recovered from clinically relevant specimens. 
MATERIALS AND METHODS 
A prospective surveillance study was conducted in 10 Korean 
hospitals (A-J). Data was collected over a one-year period 
regarding the usage of systemic antifungal agents by patients 
admitted in a particular hospital. This was then determined 
by calculating the number of defined daily doses per 1,000 
patient days (DDD/1,000 PD), as specified by the WHO ATC/ 
DDD system (www.whocc.no/atcddd/) and DDD measure- 
ment methodology7. The non-duplicated clinical isolates of 
the Candida species, which were collected from clinically 
relevant specimens over a three-month period (from October 
2016 to December 2016), were sent to Chonnam National 
University Hospital for species identification and antifungal 
susceptibility testing. The identification results of Candida 
species were obtained using the conventional laboratory tests 
of each hospital. After gathering the results, the final iden- 
tification was performed using CHROMagar Candida (BBL; 
Becton Dickinson, Sparks, MD, USA), VITEK 2 system with a 
VITEK 2 YST card (bioMérieux, Marcy l'Étoile, France), MALDI 
Biotyper (software version 3.1, reference database version 
4.0.0.1, Bruker Daltonics, Billerica, MA, USA), or sequencing, 
if further confirmation is needed8. The antifungal susceptibility 
test was performed to measure their resistance to fluconazole, 
voriconazole, amphotericin B, and micafungin, and it was 
done using the Clinical and Laboratory Standards Institute 
(CLSI) broth microdilution method M609. The minimum in- 
hibitory concentration (MIC) of each isolate was categorized 
by applying CLSI clinical breakpoints (CBPs) or epidemiological 
cutoff values (ECVs)10,11. 
RESULTS 
The data in Table 1 suggest that the total antifungal use 
varied considerably in 10 selected hospitals, ranging from 7.7 
to 158.9 DDD/1,000 PD, with fluconazole being the most 
commonly used agent (with an average of 18.6 DDD/1,000 
PD, or 37.1% of total DDD/1,000 PD), followed by ampho- 
tericin B (15.3, 30.6%), itraconazole (4.9, 9.7%), voriconazole 
(3.8, 7.5%), posaconazole (3.1, 6.3%), caspofungin (2.6, 
5.2%), micafungin (1.6, 3.2%), and anidulafungin (0.2, 0.4%), 
respectively. Table 2 summarizes the species identification 
and in vitro susceptibility to fluconazole, voriconazole, ampho- 
tericin B, and micafungin for 274 Candida isolates obtained 
from clinically relevant specimens over a three-month period. 
C. albicans (n=140, 51.1%) was the most commonly re- 
covered, followed by 43 C. glabrata (15.7%), 41 C. tropicalis 
(15.0%), 37 C. parapsilosis (13.5%), 4 C. krusei (1.5%), 3 C. 
guilliermondii (1.1%), 2 C. auris (0.7%), 1 C. fabianii (0.4%), 
1 C. lusitaniae (0.4%), 1 C. magnoliae (0.4%), and 1 C. pelli- 
culosa (0.4%) isolates. All the isolates showed an MIC range 
of 0.125 to > 64 μg/mL for fluconazole, 0.03~8 μg/mL for 
voriconazole, 0.25~2 μg/mL for amphotericin B, and 0.015~ 
breakpoints or epidemiological cutoff values to Candida isolates, the non-susceptibility rates to fluconazole, 
voriconazole, amphotericin B, and micafungin were found in 20.7%, 5.6%, 0%, and 0% of isolates, respectively. 
 
Conclusion: This nationwide multicenter study showed that total antifungal use varied considerably according to 
each hospital. Non-susceptibility to fluconazole should be further monitored, considering the drug's frequent use 
in Korea. 
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2 μg/mL for micafungin. Upon applying CBPs or ECVs to 
available Candida species, the resistance and non-susceptible 
rates for these species to fluconazole, voriconazole, ampho- 
tericin B, and micafungin were found to be 5.2% and 20.7%; 
3.3% and 5.6%; 0.0% and 0.0%; and 0.0% and 0.0%, 
respectively. 
DISCUSSION 
This nationwide multicenter study aims to investigate the 
antifungal drug usage and the antifungal susceptibility of 
Candida species recovered from clinically relevant specimens. 
We found that the total antifungal use varied considerably 
according to each hospital. The average total usage of anti- 
fungals was 50.1 DDD/1,000 PD, which was similar to reports 
shown by previous Korean multicenter studies (63.2 DDD/ 
1,000 PD in 2011 and 39.2 in 2005)3,5; however, the pattern 
of antifungal agent usage was different in each hospital. 
Fluconazole was the most commonly used agent in seven 
hospitals, while amphotericin B was the most commonly 
used in three hospitals, specifically hospitals B, C, and E. The 
average usages of fluconazole, itraconazole, voriconazole, 
amphotericin B, caspofungin, and micafungin showed a 0.6-, 
0.4-, 0.8-, 1.2-, 1.6-, and 1.1-fold increase, respectively, com- 
pared with those found in the 2011 study10. Consistent with 
previous studies, fluconazole was still the most commonly 
used antifungal agent5, but the overall echinocandin use has 
increased (average of 4.4 DDD/1,000 PD and 8.8% of total 
DDD/1,000 PD in this study; 3.1 DDD/1,000 PD and 4.9% in 
2011; 0.5 DDD/1,000 PD and 1.2% in 2005)3,5 as well. The 
use of fluconazole has been associated with an increased risk 
of candidemia caused by non-albicans Candida species due 
to their inherently higher level of resistance to certain anti- 
Table 1. Antifungal drug use in 10 Korean hospitals over a one-year period (2016) 
Antifungals 
Antifungal drug use by hospitals (defined daily dose/1,000 patient days) 
Average 
Total 
(%) A B C D E F G H I J 
Azoles 115.3 37.1 46.5 27.1 11.2 21.8 13.3 12.4 12.9 6.2 30.4 
303.9 
(60.6) 
Fluconazole 45.0 30.1 27.9 25.3 8.5 8.7 11.5 11.1 12.6 5.4 18.6 
186.0 
(37.1) 
Itraconazole 40.8 0.6 2.4 0.6 1.1 2.5 0.0 0.4 0.0 0.4 4.9 
48.6 
(9.7) 
Voriconazole 15.0 2.4 12.2 1.3 1.7 3.1 0.4 0.9 0.4 0.5 3.8 
37.8 
(7.5) 
Posaconazole 14.5 4.1 4.1 0.0 0.0 7.5 1.3 0.0 0.0 0.0 3.1 
31.4 
(6.3) 
Amphotericin B* 34.3 50.2 35.4 4.0 16.9 4.7 3.3 2.5 2.2 0.0 15.3 
153.3 
(30.6) 
Echinocandins 9.3 13.1 9.1 1.4 2.6 2.6 3.1 0.9 0.4 1.5 4.4 
44.0 
(8.8) 
Caspofungin 3.0 12.4 2.9 1.4 1.4 1.8 1.8 0.1 0.3 0.9 2.6 
26.1 
(5.2) 
Micafungin 6.3 0.7 5.3 0.0 0.6 0.7 0.9 0.8 0.0 0.5 1.6 
15.8 
(3.2) 
Anidulafungin 0.0 0.0 0.9 0.0 0.5 0.1 0.5 0.0 0.0 0.0 0.2 
2.0 
(0.4) 
Total 158.9 100.4 91.0 32.5 30.6 29.1 19.7 15.8 15.5 7.7 50.1 
501.2 
(100) 
*This category included the lipid formulations of amphotericin B 
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Table 2. Antifungal susceptibilities of 274 clinical isolates of Candida species obtained from 10 Korean hospitals over three 
months 






Number (%) of isolates classified by 
CBPs or ECVs 
Range 50% 90% R SDD or I Total 
Fluconazole 
    
 
   
C. albicans 140 0.125~2 0.25 0.5  0 (0.0) 0 (0.0)  0 (0.0) 
C. glabrata 43 4~>64 8 32  3 (7.0) 40 (93.0) 43 (100) 
C. tropicalis 41 0.125~8 0.25 1  1. (2.4) 0 (0.0)  1 (2.4) 
C. parapsilosis 37 0.25~16 1 4  3 (8.1) 2 (5.4) 5 (13.5) 
C. krusei 4 32~>64 
  
 4 (100)† NA 4 (100) 
C. guilliermondii 3 0.25~>64 
  
 1 (33.3)‡ NA 1 (33.3) 
C. auris 2 >64 
  
 NA NA NA 
C. lusitaniae 1 >64 
  
 1 (100)‡ NA 1 (100) 
C. pelliculosa 1 >64 
  
 1 (100)‡ NA 1 (100) 
Other Candida species* 2 2-64 
  
 NA NA NA 
Total 274 0.125~>64    14 (5.2) 42 (15.6) 56 (20.7) 
Voriconazole 
    
 
   
C. albicans 140 0.03~0.5 0.03 0.03  0 (0.0) 1 (0.7)  1 (0.7) 
C. glabrata 43 0.03~4 0.5 0.5  3 (7.0)‡ NA  3 (7.0) 
C. tropicalis 41 0.03~1 0.06 0.06  1 (2.4) 0 (0.0)  1 (2.4) 
C. parapsilosis 37 0.03~0.5 0.06 0.125  0 (0.0) 3 (8.1)  3 (8.1) 
C. krusei 4 0.5~4 
  
 1 (25.0) 2 (50.0) 3 (75.0) 
C. guilliermondii 3 0.25~8 
  
 2 (66.7)‡ NA 2 (66.7) 
C. auris 2 2 
  
 NA NA NA 
C. lusitaniae 1 2 
  
 1 (100)‡ NA 1 (100) 
C. pelliculosa 1 4 
  
 1 (100)‡ NA 1 (100) 
Other Candida species  2 0.06~0.125 
  
 NA NA NA 
Total 274 0.03~8    9 (3.3) 6 (2.2) 15 (5.6) 
Amphotericin B         
C. albicans 140 0.25~2 0.5 0.5   0 (0.0)‡ NA  0 (0.0) 
C. glabrata 43 0.25~1 1 1   0 (0.0)‡ NA  0 (0.0) 
C. tropicalis 41 0.5~1 1 1   0 (0.0)‡ NA  0 (0.0) 
C. parapsilosis 37 0.25-1 0.5 1   0 (0.0)‡ NA  0 (0.0) 
C. krusei 4 1     0 (0.0)‡ NA  0 (0.0) 
C. guilliermondii 3 0.25~0.5     0 (0.0)‡ NA  0 (0.0) 
C. auris 2 0.5~1    NA NA NA 
C. lusitaniae 1 0.5     0 (0.0)‡ NA  0 (0.0) 
 
JMI VOL 25. NO 1. MARCH 2020 
14 Copyright@2020 by The Korean Society for Medical Mycology 
Journal of 
Mycology and Infection 
fungal agents5. In addition, the increasing trend in echino- 
candin use is important because it could pose a risk of 
emerging echinocandin-resistant Candida species4. 
The overall epidemiology of the Candida species agreed 
with the data of previous studies conducted in Korea3,6. More 
importantly, in the current study, C. glabrata was the most 
frequently found non-albicans Candida species, followed by 
C. tropicalis and C. parapsilosis, while the 2011 study found 
slightly different rates, where C. parapsilosis (17.8%) was 
the most common non-albicans Candida species, followed 
by C. glabrata (14.4%) and C. tropicalis (12.7%)6. When 
applying CBPs, 11 of 265 Candida isolates were found to be 
resistant to fluconazole, specifically three C. glabrata, one C. 
tropicalis, three C. parapsilosis, and four C. krusei isolates. 
The overall resistance rate was not much higher than that of 
other geographic regions12,13. The fluconazole resistance and 
non-susceptibility rates, however, showed a 2.0- and 1.3-fold 
increase, respectively, compared with the data provided by 
previous Korean studies (2.6% and 16.4% in 2011, respet- 
ively)5. Moreover, among nine isolates of uncommon Candida 
species, five showed fluconazole MICs of > 64 μg/mL (two C. 
auris, one C. guilliermondii, one C. lusitaniae, and one C. 
pelliculosa isolates). Recently, C. auris has been highlighted to 
be less susceptible to fluconazole compared with the other 
Candida species, and it was reported to have developed a 
high-level resistance to fluconazole like that of C. glabrata14. 
In addition, C. auris was reported to be misidentified as C. 
haemulonii by the conventional identification method8,14. In 
the present study, two C. auris isolates were identified as C. 
haemulonii using conventional laboratory tests conducted in 
each particular hospital, which required sequencing to confirm 
the identification. Two candidemia cases with echinocandin- 
Table 2. Antifungal susceptibilities of 274 clinical isolates of Candida species obtained from 10 Korean hospitals over three 
months (Continued) 






Number (%) of isolates classified by 
CBPs or ECVs 
Range 50% 90% R SDD or I Total 
C. pelliculosa 1 1 
  
 NA NA NA 
Other Candida species* 2 0.25 
  
 NA NA NA 
Total 274 0.25~2 
  
  0 (0.0) NA  0 (0.0) 
Micafungin         
C. albicans 140 0.015~0.06 0.015 0.015   0 (0.0) 0 (0.0)  0 (0.0) 
C. glabrata 43 0.015~0.03 0.015 0.03   0 (0.0) 0 (0.0)  0 (0.0) 
C. tropicalis 41 0.015~0.06 0.015 0.03   0 (0.0) 0 (0.0)  0 (0.0) 
C. parapsilosis 37 0.015~2 1 1   0 (0.0) 0 (0.0)  0 (0.0) 
C. krusei 4 0.015~0.25 
  
  0 (0.0) 0 (0.0)  0 (0.0) 
C. guilliermondii 3 0.5~1 
  
  0 (0.0) 0 (0.0)  0 (0.0) 
C. auris 2 0.015    NA NA NA 
C. lusitaniae 1 0.06    0 (0.0)‡ NA  0 (0.0) 
C. pelliculosa 1 0.015    NA NA NA 
Other Candida species* 2 0.06~0.125    NA NA NA 
Total 274 0.015-2     0 (0.0) 0 (0.0)  0 (0.0) 
*Other Candida species included C. fabianii (one isolate) and C. magnoliae (one isolate) 
†All C. krusei isolates are considered as resistant to fluconazole, irrespective of the MIC 
‡The results were analyzed by ECVs11 
Abbreviations: MIC, minimum inhibitory concentration; CBP, clinical breakpoint; ECV, epidemiological cutoff value; SDD, 
susceptible dose-dependent; I, intermediate; R, resistant; NA, not available 
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resistant Candida isolates (C. albicans and C. glabrata) were 
reported in South Korea15; however, the researchers found 
no Candida isolate that was resistant to micafungin, con- 
firming the low resistance rates of echinocandins in South 
Korea when compared with those of the traits of micafungin 
that were documented in the previous study of other geo- 
graphic regions, such as 0.4% in North America, 0.5% in 
Europe, 0% in Latin America, and 0.3% in the Asia Pacific 
region12. 
CONCLUSION 
We investigated the nationwide antifungal use, species 
distribution, and antifungal susceptibility in South Korea. 
The overall antifungal usage was similar with the established 
previous usage, but the use of echinocandins has increased, 
which might affect echinocandin non-susceptibility rates in 
Candida species. The Candida species distribution was similar 
as it was in the past, but the rank order and frequency of non- 
albicans Candida species was changing. The overall resistance 
rates of Candida species were still low, but fluconazole re- 
sistance and non-susceptibility rates have increased in South 
Korea. Although echinocandin resistance is still uncommon 
in Korea, we should be aware of its emergence in the near 
future, considering the increment of echinocandin use. 
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